Analysis of Predictors of Resection and Survival in Locally Advanced Stage III Pancreatic Cancer: Does the Nature of Chemotherapy Regimen Influence Outcomes?

@article{Bednar2016AnalysisOP,
  title={Analysis of Predictors of Resection and Survival in Locally Advanced Stage III Pancreatic Cancer: Does the Nature of Chemotherapy Regimen Influence Outcomes?},
  author={Filip Bednar and Mazen S. Zenati and Jennifer Steve and Sharon Winters and Lee M. Ocuin and Nathan Bahary and Melissa E. Hogg and Herbert J. Iii Zeh and Amer H. Zureikat},
  journal={Annals of Surgical Oncology},
  year={2016},
  volume={24},
  pages={1406-1413}
}
BackgroundLocally advanced unresectable pancreatic cancer (LAPC) historically portends a poor prognosis. FOLFIRINOX and gemcitabine/nab-paclitaxel have proven effective in the metastatic setting. We sought to evaluate the outcomes of these regimens compared with older regimens in LAPC.MethodsA retrospective, single institutional review of all consecutive LAPC treated with “new” (FOLFIRINOX and/or gemcitabine/nab-paclitaxel) and “old” (gemcitabine or 5-FU) chemotherapy from 2010 to 2014 was… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-8 OF 8 CITATIONS

Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinoma.

  • Annals of oncology : official journal of the European Society for Medical Oncology
  • 2017
VIEW 10 EXCERPTS
CITES RESULTS
HIGHLY INFLUENCED

References

Publications referenced by this paper.
SHOWING 1-10 OF 30 REFERENCES

Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2016
VIEW 1 EXCERPT

Approach to patients with pancreatic cancer without detectable metastases.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2015
VIEW 1 EXCERPT